WO2002043774A3 - Compositions and therapeutical use of polynucleotides encoding tcrs - Google Patents

Compositions and therapeutical use of polynucleotides encoding tcrs Download PDF

Info

Publication number
WO2002043774A3
WO2002043774A3 PCT/US2001/050673 US0150673W WO0243774A3 WO 2002043774 A3 WO2002043774 A3 WO 2002043774A3 US 0150673 W US0150673 W US 0150673W WO 0243774 A3 WO0243774 A3 WO 0243774A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides encoding
compositions
therapeutical use
encoding tcrs
polynucleotides
Prior art date
Application number
PCT/US2001/050673
Other languages
French (fr)
Other versions
WO2002043774A2 (en
Inventor
Juan Harrison
Original Assignee
Powderject Vaccines Inc
Juan Harrison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US24548100P priority Critical
Priority to US60/245,481 priority
Application filed by Powderject Vaccines Inc, Juan Harrison filed Critical Powderject Vaccines Inc
Priority claimed from US10/415,745 external-priority patent/US20040048822A1/en
Publication of WO2002043774A2 publication Critical patent/WO2002043774A2/en
Publication of WO2002043774A3 publication Critical patent/WO2002043774A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Abstract

Polynucleotides encoding T-cell receptors and compositions and methods of use these polynucleotides are provided. The invention includes polynucleotides encoding at least one T-cell receptor or fragments thereof, core carriers coated with these polynucleotides and methods of treating T-cell mediated diseases in a subject.
PCT/US2001/050673 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs WO2002043774A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US24548100P true 2000-11-02 2000-11-02
US60/245,481 2000-11-02

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/415,745 US20040048822A1 (en) 2001-11-01 2001-11-01 Nucleic acid immunization
EP20010988417 EP1392365A2 (en) 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs
AU4172602A AU4172602A (en) 2000-11-02 2001-11-01 Nucleic acid immunization
JP2002545744A JP2004535358A (en) 2000-11-02 2001-11-01 Nucleic acid immunization

Publications (2)

Publication Number Publication Date
WO2002043774A2 WO2002043774A2 (en) 2002-06-06
WO2002043774A3 true WO2002043774A3 (en) 2003-12-04

Family

ID=22926841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050673 WO2002043774A2 (en) 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs

Country Status (4)

Country Link
EP (1) EP1392365A2 (en)
JP (1) JP2004535358A (en)
AU (1) AU4172602A (en)
WO (1) WO2002043774A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017697B2 (en) 2006-10-12 2015-04-28 The University Of Queensland Compositions and methods for modulating immune responses
AU2011325857A1 (en) 2010-11-01 2013-05-02 University Of Technology, Sydney Immune-modulating agents and uses therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865796A (en) * 1994-01-21 1999-02-02 Powderject Vaccines, Inc Gas driven gene delivery instrument
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6090387A (en) * 1989-03-21 2000-07-18 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses
WO2000063385A2 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090387A (en) * 1989-03-21 2000-07-18 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses
US5865796A (en) * 1994-01-21 1999-02-02 Powderject Vaccines, Inc Gas driven gene delivery instrument
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO2000063385A2 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEGANO P ET AL: "Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect? system", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 4, 1 February 1998 (1998-02-01), pages 394 - 398, XP004099300, ISSN: 0264-410X *
WAISMAN A ET AL: "SUPPRESSIVE VACCINATION WITH DNA ENCODING A VARIABLE REGION GENE OF THE T-CELL RECEPTOR PREVENTS AUTOIMMUNE ENCEPHALOMYELITIS AND ACTIVATES TH2 IMMUNITY", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 2, no. 8, 1 August 1996 (1996-08-01), pages 899 - 905, XP002073619, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
JP2004535358A (en) 2004-11-25
AU4172602A (en) 2002-06-11
EP1392365A2 (en) 2004-03-03
WO2002043774A2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
DE60330333D1 (en) Therapeutic compositions contain 1,2,3,6-tetrahydropyrimidin-2-one and corresponding methods
EP0710667B8 (en) Modified oligonucleotides, their preparation and their use
DE69739478D1 (en) Cadasil-related gene, diagnostic methods and therapeutic use
DE59915058D1 (en) Surface-modified flame retardants, processes for their preparation and their use
DE59813983D1 (en) Substituted 2-aryl-4-amino-chinazolines, method for the production thereof and their use as medicaments
DE60222804D1 (en) 3- (2,4) dihydroxyphenyl-4-phenylpyrazole and their medical use
DE60237425D1 (en) PyrazoloÄ4,3-diphyrimidines, process for their preparation and therapeutic use
DE60207937D1 (en) use braking apparatus and method, the Ni-W alloy plating
DK1383650T3 (en) Rörformede polymeric composites for rör- and hose constructions
HK1027877A1 (en) Rhythm game apparatus, rhythm game method and instrumental device.
DK1019358T4 (en) 3,3-diarylpropylamines, their use and preparation
AU2002337047A1 (en) Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
DE60103182D1 (en) Methansufonamido-benzofuran, manufacturing process and its use as synthetic intermediate
IL150085D0 (en) New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
AT296509T (en) Flexible user distribution between user service units
AU2001266592A1 (en) Radiation delivery devices and methods for their manufacture
DE60116784D1 (en) The patient directed therapy management
AU2002363253A1 (en) Endothelial-cell binding peptides for diagnosis and therapy
EE200000366A (en) The device and the method for treating body tissues, drugs or electrical
DE50107641D1 (en) Coating and binding agent for drug formulations with improved storage stability
NO20042344L (en) Multiple analog and digital downconversion
AU5312601A (en) (+) naloxone and epinephrine combination therapy
DE60206837D1 (en) The implantable medical device with anchoring elements
GB0110161D0 (en) Polymer treatment
DE60029015D1 (en) Dental materials with extended processing time, kits and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002545744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001988417

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10415745

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001988417

Country of ref document: EP